🆕 Visual Abstract w/ Healio Rheumatology 🟢

#Telitacicept in Systemic Lupus
• telitacicept: TACI-Fc fusion protein which targets BLyS/APRIL
• telitacicept: ⇡ response rate vs PBO

📖: van Vollenhoven et al, NEJM
📎: tinyurl.com/telitacicepthealio

#Lupus #MedSky #RheumSky
@gohealio.bsky.social

Sjögren-Syndrom: Gleich zwei erste spezifische Arzneistoffe in Sicht Das Sjögren-Syndrom ist vor allem durch Mund- und Augentrockenheit gekennzeichnet; systemische Manifestationen sind möglich. Nun könnte demn...

Das #Sjögren-Syndrom ist vor allem durch Mund- und Augentrockenheit gekennzeichnet; systemische Manifestationen sind möglich. Nun könnten demnächst erstmals spezifisch zugelassene Medikamente auf den Markt kommen. Für #Telitacicept und #Ianalumab wurden nun Phase-III-Daten präsentiert.

Key Findings from Telitacicept's Phase III Trial in Sjögren's Syndrome Unveiled at ACR 2025 The release of Phase III trial results for Telitacicept reveals significant improvements in Sjögren's Syndrome treatment. Explore the impactful data presented at the 2025 ACR.

Key Findings from Telitacicept's Phase III Trial in Sjögren's Syndrome Unveiled at ACR 2025 #China #Yantai #RemeGen #Telitacicept #Sjögren's_Syndrome

Telitacicept Phase III Study Results for Myasthenia Gravis Highlighted for AANEM 2025 Presentation RemeGen's Phase III clinical study results for telitacicept in generalized myasthenia gravis will be presented at the 2025 AANEM Annual Meeting, showcasing its promising potential.

Telitacicept Phase III Study Results for Myasthenia Gravis Highlighted for AANEM 2025 Presentation #China #Yantai #RemeGen #Myasthenia_Gravis #Telitacicept

RemeGen's Telitacicept Achieves Success in Phase III Trial for Sjögren's Syndrome RemeGen's drug Telitacicept has successfully met its primary endpoint in a Phase III trial for primary Sjögren's syndrome in China.

RemeGen's Telitacicept Achieves Success in Phase III Trial for Sjögren's Syndrome #China #Yantai #RemeGen #Telitacicept #Sjögren's_Syndrome

Response to telitacicept in optic neuritis associated with Sjogren's syndrome: a case report and literature review ON associated with Sjögren syndrome is uncommon and easily misdiagnosed. Conventional therapies for ON cannot control recurrence, but this case suggests telitacicept might be a promising option.

#MedCase - Optic neuritis associated with Sjögren syndrome is uncommon and easily misdiagnosed.

Conventional therapies for ON cannot control recurrence, but this case suggests #telitacicept might be a promising option.

👉 buff.ly/BQH2PFy

#NeuroSky #EyeSky

RemeGen's Telitacicept Receives EMA's Orphan Drug Designation for Myasthenia Gravis Therapy RemeGen's Telitacicept has received Orphan Drug Designation from the EMA, enabling faster access for Myasthenia Gravis patients in Europe.

RemeGen's Telitacicept Receives EMA's Orphan Drug Designation for Myasthenia Gravis Therapy #China #Yantai #RemeGen #Myasthenia_Gravis #Telitacicept

RemeGen's Telitacicept Receives Approval for Myasthenia Gravis in China RemeGen's innovative drug Telitacicept has been greenlit by China's NMPA for the treatment of generalized myasthenia gravis, heralding new hope for patients.

RemeGen's Telitacicept Receives Approval for Myasthenia Gravis in China #China #Yantai #RemeGen #Myasthenia_Gravis #Telitacicept

RemeGen Unveils Promising Phase 3 Results of Telitacicept for Myasthenia Gravis Treatment Telitacicept shows remarkable efficacy in Phase 3 trials for generalized myasthenia gravis, potentially transforming treatment for patients.

RemeGen Unveils Promising Phase 3 Results of Telitacicept for Myasthenia Gravis Treatment #USA #San_Diego #RemeGen #Myasthenia_Gravis #Telitacicept